RT Journal Article
SR Electronic
T1 Elevation of Neurodegenerative Serum Biomarkers among Hospitalized COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.01.21262985
DO 10.1101/2021.09.01.21262985
A1 Frontera, Jennifer A.
A1 Boutajangout, Allal
A1 Masurkar, Arjun V.
A1 Betensky, Rebecca A.
A1 Ge, Yulin
A1 Vedvyas, Alok
A1 Debure, Ludovic
A1 Moreira, Andre
A1 Lewis, Ariane
A1 Huang, Joshua
A1 Thawani, Sujata
A1 Balcer, Laura
A1 Galetta, Steven
A1 Wisniewski, Thomas
YR 2021
UL http://medrxiv.org/content/early/2021/09/05/2021.09.01.21262985.abstract
AB INTRODUCTION Older adults hospitalized with COVID-19 are susceptible to neurological complications, particularly encephalopathy, which may reflect age-related neurodegenerative processes.METHODS Serum total tau, ptau-181, GFAP, NFL, UCHL1, and amyloid-beta(Aβ-40,42) were measured in hospitalized COVID-19 patients without a history of dementia, and compared among patients with or without encephalopathy, in-hospital death versus survival, and discharge home versus other dispositions using multivariable Cox proportional hazards regression analyses.RESULTS Among 251 patients, admission serum ptau-181 and UCHL1 were significantly elevated in patients with encephalopathy (both P<0.05) and total tau, GFAP, and NFL were significantly lower in those discharged home(all P<0.05). These markers correlated significantly with severity of COVID illness. NFL, GFAP and UCH-L1 were significantly higher in hospitalized COVID patients than in non-COVID controls with mild cognitive impairment or Alzheimer’s disease(AD).DISCUSSION Age-related neurodegenerative biomarkers were elevated to levels observed in AD and associated with encephalopathy and worse outcomes among hospitalized COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: NIH/NIA (Wisniewski) COVID-19 administrative supplement 3P30AG066512-01 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NYU Langone Health IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request